Neuroactive Steroid GABA Modulators for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CNS-related disorders lack effective modulators of GABA activity, and existing drugs have limitations in their therapeutic scope and side effects.
Innovation Solution
Development of novel compounds, specifically those represented by Formulas (I) and (II), which act as GABA modulators, designed to treat CNS-related disorders by interacting with specific sites on the GABA receptor complex, including neuroactive steroid binding sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing GABA-modulating drugs (barbiturates and benzodiazepines) are used to treat CNS disorders, then therapeutic effects are achieved through interaction with benzodiazepine and barbiturate binding sites, but the therapeutic scope is limited and side effects occur
Solution Approach 1:
The patent introduces neuroactive steroid binding sites as intermediary targets on the GABA receptor complex. By designing compounds that interact with these distinct sites rather than the conventional benzodiazepine or barbiturate sites, the invention achieves a different mechanism of action that can modulate GABA activity with potentially reduced side effects and expanded therapeutic scope for CNS disorders
Solution Approach 2:
The invention changes the binding parameter from conventional sites to neuroactive steroid binding sites on the GABA receptor complex. This parameter change in the interaction site allows for novel compounds with different pharmacological profiles, aiming to improve therapeutic versatility while reducing harmful side effects associated with traditional GABA-modulating drugs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide therapeutic benefits by modulating brain excitability, offering potential treatments for anxiety, seizure activity, and sedation, with a focus on improved efficacy and reduced side effects compared to existing drugs.
Implementation Method 1
GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell
Data Source
AI summary
Provided herein is a compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of using the compound of Formula (I) in the treatment of CNS-related disorders.